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1. Introduction
Gliomas are the most common tumors of the brain. Normal glia includes astrocytes, oligo‐
dendrocytes, and ependyma. Gliomas are analogously designated as astrocytomas, oligo‐
dendrogliomas, and ependymomas to reflect the non-neoplastic cell types that they most
closely resemble.
Gliomas can also be classified histologically as astrocytomas, oligodendrogliomas, or tumors
with morphological features of both astrocytes and oligodendrocytes. The 2007 World
Health Organization (WHO) classification recognizes three main histologic types of low
grade diffuse glioma grade II: diffuse astrocytoma, oligoastrocytoma, and oligodendroglio‐
ma [1]. Diffuse astrocytomas account for approximately 40% of primary intracranial tumors.
Their gross, microscopic, and biologic characteristics vary to a considerable degree accord‐
ing to their site. They occur at all ages, although the median age is 30 to 40 for astrocytoma
(grade II), 40 to 50 for anaplastic astrocytoma (grade III), and 50 to 60 years for glioblastoma
multiforme (grade IV). Diffuse astrocytomas tend to progress to more malignant histologic
types, such as anaplastic astrocytoma (WHO grade III) and sometimes secondary glioblasto‐
ma (WHO grade IV). Oligodendrogliomas account for approximately 5% of intracranial
gliomas. They are most often found in the cerebral hemispheres, where they usually involve
the cortex and the white matter. Traditionally the prognosis of oligodendrogliomas has been
regarded as relatively favorable, but in practice no valid correlation has been established be‐
tween the microscopic appearances of these tumors and their clinical evolution. Progression
of oligodendrogliomas to anaplastic oligodendrogliomas can be unpredictable. Glioblasto‐
mas are malignant, rapidly fatal, astrocytic neoplasms. Glioblastomamultiforme (GBM), ac‐
count for 30% of primary brain tumors in adults [2, 3]. Patients with
glioblastomamultiforme have a mean survival of about 12 months. They may occur in any
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region of the central nervous system, however, the cerebral hemispheres, in particular the
frontal lobes or temporal lobes, the basal ganglia, and the commissural pathways are sites of
predilection. Most GBMs are diagnosed as de novo or primary tumors and are more com‐
mon in males. A subset of about 5% of GBM tumors, termed secondary GBM, progress from
lower-grade tumors (grade II/III), are seen in younger patients, are more evenly distributed
among the sexes, and exhibit longer survival times [4]. Depending on the grade and mor‐
phologic type of glioma, newly diagnosed patients receive watchful waiting, surgical resec‐
tion, radiotherapy, or chemotherapy, or some combination of these therapies.
Chemotherapy for GBM has very limited efficacy, however it has been shown that certain
patients may respond to some treatments [5, 6]. Temozolomide is a novel alkylating agent
that has demonstrated activity in recurrent gliomas [7-9]. Regardless of therapy, most pa‐
tients will progress and have a high risk of mortality and reduced quality of life. For these
reasons there has been a great deal of interest in understanding the biology and genetics of
gliomas, to provide better diagnostic tools and new therapeutic approaches [10]. Molecular
pathology markers are being identified that have been or will soon prove to be clinically
useful in treatment of glioma patients.
Molecular genomic-based laboratory assays are often used for detection of prognostic and pre‐
dictive markers in gliomas. Research efforts have identified a number of cytogenetic and mo‐
lecular  genetic  alterations  in  gliomas  [11]  that  may  be  exploited  to  facilitate  glioma
classification, especially in cases that exhibit inconclusive or borderline histologic features.
This chapter will focus on those molecular biomarkers that have been established in glioma di‐
agnostics, namely MGMT promoter methylation, 1p/19q Loss of Heterozygosity (LOH), IDH1
and IDH2 mutations, and epidermal growth factor variant III (EGFRvIII) mutations. Emphasis
will be placed on clinical applications, most frequently used methods of detection, as well as is‐
sues involved in assay validation, specimen selection, and clinical laboratory oversight.
1.1. MGMT promoter methylation
Chemotherapy for GBM has very limited efficacy, however it has been shown that certain
patients may respond to some treatments. Temozolomide is a novel alkylating agent that
has demonstrated activity in recurrent gliomas. Alkylating agents cause cell death by form‐
ing cross-links between adjacent strands of DNA due to alkylation of the O6 position of gua‐
nine. The O6-methylguanine-DNA methyltransferase (MGMT) gene produces the cellular
DNA repair protein O6-alkylguanine DNA alkyltransferase (AGT) which is a key factor in
resistance to alkylating agents. It functions as a DNA repair enzyme that removes the muta‐
genic alkyl-adducts from the O6-poasition of guanine, and this transfer of alkyl groups to
AGT prevents the formation of lethal cross links in DNA. Tumors appear to be heterogene‐
ous with respect to MGMT expression, and in a subset of cancer cells, its expression is si‐
lenced due to abnormal promoter methylation. Aberrant methylation of CpG islands located
in the promoter region of MGMT gene is associated with transcriptional inactivation of this
gene, and consequent low levels of the MGMT DNA repair enzyme. Studies have shown
that patients with low levels of this DNA repair enzyme are more likely to experience re‐
sponse to therapy and prolonged overall and disease free survival [12-15].
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DNA methylation (for more detailed description and references please see [16]) is a mecha‐
nism by which the cell regulates gene expression. Methylation is an enzyme mediated modi‐
fication that adds a methyl (-CH3) group at a selected site on DNA or RNA. In humans,
methylation occurs only at cytosine (C) bases followed by a guanosine (G), also known as
CpGdinucleotides. The CpG dinucleotides are prone to spontaneous mutations and have
been selectively depleted from mammalian genome. However, some regions of DNA have
retained CpGdinucleotides and are referred to as CpG islands. The CpG islands are found
primarily in the 5' region of expressed genes, often in association with promoters. When the
promoter CpG island is methylated, the corresponding gene is silenced and transcription
does not occur. Aberrant CpG island methylation of tumor suppressor genes is frequent in
cancer and appears to be an important mechanism of neoplastic transformation.
Quantitative evaluation on methylated MGMT in tumors suggests that not all cells in a tu‐
mor positive for promoter methylation carry a methylated MGMT allele. This raises the
question of what level of promoter methylation has clinical significance. A recent study [17]
investigated the degree and pattern of MGMT promoter methylation in paired samples of
glioblastoma tissue and glioblastoma-derived spheres. The degree and density of MGMT
methylation was then compared with the chromatin structure of MGMT, gene dosage, gene
expression and enzyme activity, and the tumor cell content of the patient samples. Ten
paired samples were evaluated for the extent and density of methylation by clone sequenc‐
ing 28 of 97 CpGs in the CpGisland of the MGMT promoter. This region of the promoter en‐
compasses the enhancer element and, according to reporter assays, is associated with
complete silencing of the gene when fully methylated [18]. Most assays interrogate CpG
methylation in this region. For all glioblastomas with MGMT methylation, a band for unme‐
thylated alleles was also detectable, which is expected since benign cells will always be
present in the specimen. Sequencing of the original glioblastoma tissue revealed that 10% to
90% of all clones sequenced showed dense methylation, arbitrarily defined as at least 4 con‐
secutive CpGs methylated in a given interrogated clone. The density of MGMT promoter
methylation, defined as the number of methylated CpGs over 28 interrogated CPGs, ranged
from 25% to 90%, never reaching 100%, and showing a characteristic pattern for each tumor.
The study [17] further showed that MGMT methylation is associated with no or low MGMT
expression and closed chromatin structure. MGMT activity was below the limit of detection
in glioblastoma spheres of completely methylated cases. Moderate activity was measured in
the case with one unmethylated allele, and the unmethylated case showed the highest activi‐
ty. MGMT activity was measurable in all respective original tissues likely due to contami‐
nating normal cells. In accordance with lack of MGMT expression and MGMT activity, the
closed chromatin pattern was also observed. Marks of active and inactive chromatin pattern
were observed for unmethylated and partially methylated cases.
As combined chemoradiotherapy comprising the alkylating agent temozolomide has be‐
come the new standard of care [19], there has been growing interest to use MGMT promoter
methylation status for individual patient management, and for patient stratification or selec‐
tion in clinical trials. Knowledge of MGMT promoter methylation status is relevant for both
prognostic and predictive considerations. Furthermore, MGMT promoter methylation status
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has been used as a stratifying factor or eligibility criterion in ongoing and accruing clinical
trials [20].
Aberrant methylation of CpG islands in the promoter region of many genes has been recog‐
nized as an important epigenetic mechanism for gene silencing [21-24]. Inactivation of mul‐
tiple tumor suppressor genes by aberrant hypermethylation is a fundamental process
involved in the development of many malignant tumors [25, 26]. Mapping of methylation
patterns in CpG islands has become an important tool in understanding tissue-specific gene
expression in both normal and pathologic situations, and several protocols have been pub‐
lished for evaluating methylation status by methylation-specific PCR (MSP). Most of these
protocols are based on bisulfite treatment of isolated DNA [27, 28]. Bisulfite treatment chem‐
ically changes unmethylated, but not methylated, cytosines to uracil. Methylated DNA can
be distinguished from unmethylated DNA using sodium bisulfate treatment of DNA, which
converts unmethylated C to uracil (U) but leaves methylated C intact. Detection of methyla‐
tion or lack of it involves analysis of bisulfite-treated DNA using primer pairs that specifi‐
cally identify either methylated or unmethylated DNA.
The methylated and unmethylated sequences are detected through the use of methylation-
specific primers.
Figure 1. MGMT promoter methylation detection by methylation specific PCR. Methylated bands (M) can be seen in
samples S1 and S2 and in methylated control (M). Unmethylated bands (U) are seen in S1, S2, S3, and in negative (un‐
methylated) control
Methylation Specific PCR (MSP): Methylation is a chemical modification that adds methyl
(CH3) groups at selected sites on protein, DNA and RNA. In humans, DNA methylation only
affects the cytosine base (C) when it is followed by a guanine (G). Most CpG islands have been
observed in the 5’ promoter regions of genes. When promoter CpG islands become methylat‐
ed, the associated gene is silenced. Small amount of DNA, including those from paraffin em‐
bedded tissue, can be used for testing. DNA is first treated with bisulfite which converts
unmethylated, but not methylated, cytosine to uracil. This modified DNA is then used as a
template for PCR. The sequence differences between methylated and unmethylated DNA af‐
ter bisulfite treatment allow the designing of PCR primers that are specific for each type. The
primers are intended to amplify the identified region of the promoter mentioned above. PCR
products are detected by gel electrophoresis or by capillary electrophoresis.
Methylight Protocol: The MethyLight assay utilizes the TaqMan PCR principle which re‐
quires forward and reverse primers as well as an oligomeric probe which emits fluorescence
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only after it is degraded by the 5’-3’ exonuclease activity of Taq polymerase. MethyLight
protocol is a simple, real-time PCR method to determine the methylation status of CpG is‐
lands. Collagen 2A1 (COL2A1) gene is used as the internal reference (amplification control)
to assess the quality and quantity of input DNA.
Pyrosequencing: This is a method of DNA synthesis based on sequencing by synthesis prin‐
ciple. The procedure involves taking a single strand of the DNA to be sequenced and then
synthesizing its complementary strand enzymatically. The pyrosequencing method is based
on detecting the activity of DNA polymerase with another chemiluminescent enzyme [29,
30]. The pyrosequencing reaction occurs in 5 steps. In step 1, a sequencing primer is hybri‐
dized to a single-stranded amplicon that serves as a template, and incubated with the en‐
zymes DNA polymerase, ATP sulfurylase, luciferase, and apyrase, as well as substrates
adenosine 5' phosphosulfate and luciferin. In subsequent steps triphosphates are added to
reaction and each incorporation event is accompanied by release of pyrophosphate PPi). The
PPi is subsequently converted to ATP which then drives conversion of luciferin to oxyluci‐
ferin that generates visible light. Addition of dNTPs is performed sequentially. As the proc‐
ess continues, the complementary DNA stand is built up and the nucleotide sequence is
determined from the signal peaks in the pyrogram trace.
Methylation-Specific MLPA (MS-MLPA): The multiplex ligation-dependent probe amplifi‐
cation (MLPA) method allows for multiplex detection of gene copy number aberrations in a
routine laboratory. The methylation-specific MLPA (MS-MLPA) can detect changes in both
CpG methylation as well as copy number of up to 40 chromosomal sequences in a simple
reaction. In MS-MLPA, the ligation of MLPA probe oligonucleotides is combined with di‐
gestion of the genomic DNA-probe hybrid complexes with methylation-sensitive endonu‐
cleases [31, 32]. MS-MLPA is not based on bisulfite conversion of unmethylatedcytosines,
can provide methylation status, is semiquantitative, and can be used to evaluate methyla‐
tion status of multiple sequences simultaneously. Furthermore, it allows for a combined
copy number detection and methylation-specific analysis.
1.2. 1p/19q Loss of heterozygosity(LOH)
Among the major subtypes of gliomas, oligodendrogliomas are distinguished by their remark‐
able sensitivity to chemotherapy, with approximately 70% of anaplastic (malignant) oligoden‐
drogliomas  responding  dramatically  to  treatment  with  procarbazine,  lomustine,  and
vincristine (termed PCV) [33]. Unfortunately, no clinical or pathologic feature allows accurate
prediction of chemotherapeutic response. The prognosis for grade II oligodendrogliomas is
significantly better than that for grade II astrocytomas, with average survival times of 10 to 15
years. As with astrocytomas, there is considerable individual variability in time to progres‐
sion and overall survival. The average survival for anaplastic grade III oligodendrogliomas is 3
to 5 years, although some patients with genetically favorable subset may survive 10 years or
longer. The histologic distinction between oligodendroglioma and astrocytoma is often highly
subjective, and there has been significant interobserver variation.
Patients with oligodendroglial tumors are often stratified into therapeutic groups according
to age, extent of resection, tumor grade, and 1p/19q status. The current national Comprehen‐
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sive Cancer Network (NCCN) guidelines for central nervous tumor cancers recommend
testing for 1p/19q codeletion or unbalanced translocation, for cases of suspected oligoden‐
droglioma. The test is also recommended to distinguish anaplastic oligodendroglioma from
anaplastic astrocytomas and glioblastomas. Recent studies [34-36] have shown that: (1) - al‐
lelic loss (loss of heterozygosity) of chromosome arm 1p is a statistically significant and cur‐
rently the best predictor of chemosensitivity; (2) combined loss involving chromosome arms
1p and 19q predicts both chemotherapeutic response and longer survival in patients with
oligodendrogliomas; and (3) combined allelic loss of chromosomes 1p and 19q can be con‐
sidered a molecular signature of oligodendroglioma (present in approximately 70-80% of
oligodendroglial tumors and in only 10% of astrocytomas). Anaplastic oligodendrogliomas
with loss on 1p, or combined loss on 1p and 19q usually respond favorably to chemothera‐
py, with about half of such tumors showing complete neuroradiological response. Owing to
the major prognostic significance of the 1p/19q status in patients with anaplastic gliomas
treated with radio and/or chemotherapy, ongoing prospective trials are no longer stratifying
anaplastic glioma patients according to histological types but according to the 1p/19q dele‐
tion status [37]. Detection methods for 1p and 19q deletion include polymerase chain reac‐
tion (PCR), fluorescent in situ hybridization (FISH), array comparative genomic
hybridization, and multiplex ligation-dependent probe amplification (MPLA) [38-40].
Primary Markers Back up markers
Microsatellite Locus Abbreviation Microsatellite Locus Abbreviation
D1S548 1-1 D1S468 1-2
D1S592 1-3 D1S1612 1-5
D1S552 1-4 D1S496 1-6
D19S219 19-1
D19S412 19-2 D19S606 19-3
PLA2G4C 19-5 D19S1182 19-4
Table 1. Primary and back up microsatellite markers for detection 1p and 19q deletion
1.3. 1p/19q LOH - Microsatellite-based method of detection
Allelic loss is assessed by PCR assay in normal DNA / tumor DNA pairs using markers at
both 1p and 19q. For this type of testing, a patient's blood sample is needed to accurately
assess patient's genotype and establish the normal DNA baseline. Because there might be
partial as well as complete deletions, any reductions in tumor peaks can then accurately be
interpreted as deletions. The 6 markers on 1p and the 5 markers on 19q are microsatellites (2
or 4 nucleotide repeats) except PLA2G4C which is a minisatellite (26 nucleotide repeat)
polymorphism. The markers were selected based on heterozygosity score, amplicon size,
and ease of interpretation. LOH at all informative loci on each chromosomal arm represents
the typical finding in oligodendrogliomas with 1p and 19q deletion. To streamline the work
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flow process, a set of primary markers in tested first. If at least two markers for 1p and two
marker for 19q show either no deletion or clear deletion, the results can be considered valid.
If the results with primary markers are not clear, either because the markers are not infor‐
mative (homozygosity), or they did not amplify, then the back up markers are used in sub‐
sequent PCR reaction.
 
Figure 2. The tumor sample on the left demonstrates 1p deletion. Normal DNA baseline is on the top.
 
Figure 3. Sample on the left demonstrates two alleles both in base line sample and in tumor sample. The sample on
the right has a non-informative microsatellite marker.
Array Comparative Genomic Hybridization (aCGH) - aCGH is a technique to detect genom‐
ic copy number variations at a higher resolution level than chromosome-based comparative
genomic hybridization (CGH). DNA from a test sample and normal sample are labeled dif‐
ferentially, using different fluorophores, and hybridized to several thousand probes. The
probes are derived from known genomic sequences and are printed on glass slides. The flu‐
orescence intensity of the test and of the reference DNA is then measured to calculate the
ratio between them and subsequently the copy number changes for a particular location in
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the genome. This method allows one to detect microdeletions and chromosomal duplica‐
tions and is used with increasing frequency for loss of heterozygosity detection [41].
1.4. IDH1 and IDH2 mutations
Point mutations in the cytosolic isocitrate dehydrogenase enzyme gene (IDH1) or the mito‐
chondrial version of the same gene (IDH2) are frequently detected in low grade astrocyto‐
mas, oligodendrogliomas and in secondary glioblastomas. IDH1 is involved in the metabolic
conversion of isocitrate to alpha-ketoglutarate, which reduces NADP to NADPH. In glio‐
mas, mutations in this gene were discovered through large scale DNA sequencing of tumor
samples [42]. Among WHO grade II and grade III gliomas, 50% to 80% have mutated IDH1,
whereas 5% to 10% of WHO grade IV gliomas carry IDH1 mutation. Studies of clinical trial
samples of low grade gliomas showed that mutated IDH1 may be both prognostic and pre‐
dictive, because it was associated with longer survival times and better response to temozo‐
lomide therapy [43, 44]. Another study with astrocytoma showed an association with
improved survival but not with response to temozolomide [45]. Further clarification of the
correlation of chemotherapy response and IDH1 mutational status will be needed for this
marker to receive broad clinical use. At present, lack of IDH1 mutation can not be consid‐
ered strong enough evidence to alter therapy.
Because the presence of an IDH mutation is considered tumor specific, it has a role as a diag‐
nostic marker when morphologic features are inconclusive and a non neoplastic (reactive)
condition is possible.
Nt# Nucleotide Change Amino Acid Change Frequency (%)(Hartman, 2009)
395 IDH1 G395ACGT à CAT Arg132His, R132H 92.7
394 " C394TCGT à TGT Arg132Cys, R132C 4.2
394 " C394ACGT à AGT Arg132Ser, R132S 1.5
394 " C394GCGT à GGT Arg132 Gly, R132G 1.4
395 " G395TCGT à CTT
Arg132Leu,
R132L 0.2
515 IDH2 G515AAGG à AAG Arg172Lys, R172K 64.5
515 " G515TAGG à ATG Arg172Meth, R172M 19.3
514 " A514TAGG à TGG Arg172Trp, R172W 16.2
Table 2. IDH 1 and IDH2 mutations and resulting amino acid changes
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Sanger Sequencing - The ability to sequence DNA has been essential to the field of molecu‐
lar pathology because sequence information is needed for primer design in PCR-based as‐
says, for determination of target sequence, and for detection of any changes such as
mutations, insertions and deletions in DNA sequence. The method for DNA sequencing de‐
veloped by Sanger [46] is the basis for most DNA sequencing currently performed in clinical
molecular laboratories. The Sanger sequencing reaction (for more detailed description see
[16]) uses a single DNA primer and DNA polymerase with linear amplification rather than
the exponential amplification of PCR. Components essential to the Sanger sequencing reac‐
tion include: (1) an electrophoresis technique capable of clearly distinguishing single nucleo‐
tide length differences in DNA strands dozens or hundreds nucleotides in length, (2)
sequence-specific complementary primers, with one primer used in the forward reaction
and the other used in reverse reaction for each DNA template strand, and (3) the addition of
small proportions of dideoxynucleoside triphosphates (ddNTPs) in addition to the conven‐
tional deoxyribonucleoside triphosphates (dNTPs) used in polymerase chain reaction. Di‐
deoxynucleotides differ from deoxynucleotides by having a hydrogen atom attached to the
3' carbon rather than an OH group, which is present on the deoxynucleotide. Because the
ddNTPs lack a 3'-hydroxyl group, elongation of the newly polymerized chain cannot occur
once a ddNTP has been incorporated. The end result is a set of fragments of different
lengths complementary to the parent DNA strand. The sequencing reaction products are
most frequently detected by capillary electrophoresis on a DNA sequencing instrument.
 
Figure 4. Sanger sequencing for IDH1 mutation detection: IDH1 wild type sequence (top) and CGT>CAT, p.R132H mu‐
tant (bottom)
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Immunohistochemistry: Approximately 90% of IDH1 mutated proteins can be detected by
using immunohistochemistry with a monoclonal antibody that detects p.R132H, the most
common IDH1 mutation [47].
1.5. EGFRvIII mutation detection in glioblastomamultiforme
The epidermal growth factor receptor (EGFR) is an attractive molecular target in glioblasto‐
ma because it is amplified, overexpressed, and/or mutated in up to 40% to 50% of patients.
EGFR variant III (EGFRvIII) is an oncogenic, constitutively active mutant form of EGFR that
is commonly expressed in glioblastoma. EGFRvIII is generated by in-frame genomic dele‐
tion of 801bp from exons 2 to 7 of the coding region of EGFR which produces a truncated
receptor lacking a portion of extracellular ligand binding domain. EGFRvIII mutations in
gliomas typically lead to unique signal transduction properties to the receptor, particularly
enhanced downstream activation of a phosphatidylinositol 3'-kinase (PI3K) signaling path‐
way with concurrent loss of PTEN. Cell culture and in vivo models of glioblastoma have
demonstrated EGFRvIII as defining prognostically distinct subgroups of glioblastomas. Ad‐
ditionally, the presence of EGFRvIII has been shown to sensitize tumors to EGFR tyrosine
kinase inhibitors when the tumor suppressor protein PTEN is intact [48, 49].
Expression of EGFRvIII is associated with favorable clinical response to the EGFR kinase in‐
hibitors gefitinib and erlotinib when the tumor suppressor protein PTEN is intact
EGFRvIII also presents a unique antigenetic target on tumor cells that is currently being
therapeutically used with anti- EGFRvIII vaccines as a molecularly targeted treatment ap‐
proach. In addition to its recently shown relevance for defining prognostically distinct sub‐
groups, EGFRvIII detection is likely to be increasingly important for determining treatment
decisions for patients with glioblastoma and potentially for those with other types of cancer.
RT-PCR-Based Detection - Reverse transcription-polymerase chain reaction (RT-PCR) is an
RNA-based PCR assay [50]. Reverse transcriptase catalyzes DNA synthesis using RNA as
the template, producing a DNA strand complementary to the RNA template, called comple‐
mentary DNA (cDNA). Because cDNA is not subject to RNase degradation, it is much more
stable in laboratory environment than corresponding RNA. For EGFRvIII detection, RNA is
extracted from FFPE tissue and reverse transcribed into cDNA. PCR is performed and PCR
products are detected by gel electrophoresis. PCR primers are designed to detect EGFRvIII
sequences but not unmutated sequences. A portion of a control gene is amplified in parallel
to test for RNA/cDNA yield and integrity.
2. Testing and quality control issues
2.1. Specimen types
Formalin-fixed paraffin-embedded tissue - most frequently used in clinical testing, both for
DNA-based and RNA-based analysis. Fresh and frozen tissue can be used to extract DNA or
RNA, however it is less frequently used in clinical molecular laboratories.
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Figure 5. Gliosarcoma, WHO grade IV. (A and B) Sections show a moderately pleomorphic, biphasic glial tumor. Tu‐
mor tissue tested positive for MGMT promoter methylation (C) and negative for IDH1 mutation (D).
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Microdissection may need to be performed to enrich for tumor content. If a specimen contains
too few tumor cells or too many background reactive cell types, the sensitivity of the test may
be diminished. In the past 15 years, various techniques of microdissection have been em‐
ployed to isolate cells of interest in order to increase test sensitivity. Most frequently, a pathol‐
ogist will examine an H&E stained tissue section and mark areas of tumor involvement.
Tissues from tumor rich areas are then manually scrapped off the slides and used for nucleic
acid extraction. Less frequently, laser capture microdissection might be performed, however
this method is not practical for use in routine clinical molecular laboratories.
2.2. Nucleic acid extraction
Nucleic acid purification begins with lysis of the cells in the sample. Cell lysis liberates cellu‐
lar macromolecules including proteins, lipids, and nucleic acids. Cell lysis can be accom‐
plished using a detergent solution to break cell membranes and remove lipids. Proteins are
enzymatically degraded with protease, usually proteinase K, or selectively precipitated. Pro‐
tein digestion is performed at about 56oC and will permanently denature many proteins but
does not affect nucleic acids. This process is followed by selective extraction that takes ad‐
vantage of the physical and chemical differences between nucleic acids and other cellular
molecules, forming the basis for their isolation. The nucleic acid is then purified from the
soluble contaminants produced in the extraction process by precipitation in an ethanol-salt
solution. The isolated nucleic acid is then resuspended in a dilute salt buffer.
2.3. DNA
PCR-based genetic analyses most frequently require isolated genomic DNA. Molecular anal‐
yses of nucleic acids have traditionally required DNA derived from blood, bone marrow as‐
pirate, and fresh or frozen tissues. New developments in DNA extraction methods now
make it possible to also use DNA extracted from formalin-fixed, paraffin-embedded (FFPE)
tissues. The purpose of DNA isolation/extraction procedures is to obtain useful samples of
DNA that are free of contaminating molecules which could hinder downstream DNA analy‐
sis. DNA is a hardy molecule present at stable cellular levels. It is relatively easy to isolate
and store because deoxyribonucleases (DNases) that could potenitially degrade isolated
DNA are easily denatured by heating or inhibited by sequestration of divalent cations.
2.4. RNA
Gene expression protocols (RT-PCR based genetic analyses) require isolated human RNA.
RNA analysis depends on successful RNA isolation and preservation. Total RNA is purified
with the use of RNA purification kits by first adding the white blood cells or tissue samples to a
detergent/salt solution to lyse and homogenize the cells and eliminate endogenous RNase ac‐
tivity. Homogenization disrupts the cell membranes releasing RNA into the lysing solution,
and shears the genomic DNA to reduce its ability to bind to the purification column with the
RNA. The lysates are then passed through a purification column to bind the RNA and wash
away proteins, DNA and other contaminants. Residual DNA is removed by an on-column
DNase treatment. Finally, the purified RNA is eluted with DEPC-treated water.
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2.5. Limitations of nucleic acid-based procedures
The following can affect the quality of lab results and should ideally be addressed during
assay validation:
1. The accumulation of normal cells in the tumor, including infiltrating lymphocytes, may
complicate accurate assessment of MGMT promoter methylation. Review of tissue mor‐
phology by a pathologist prior to testing will ensure that best suited tissue block are ex‐
amined.
2. Excessive necrosis of tumor tissue will complicate analysis; a different tissue block
needs to be selected, when available.
3. Bisulfite treatment of DNA is technically the most challenging part of this protocol.
Since DNA loss routinely occurs during bisulfite treatment; it is important to select cas‐
es with minimal necrosis to ensure adequate yield of DNA. In order to control for bisul‐
fite effect, methylated and unmethylated controls must be treated in parallel to patient
samples to ensure that complete conversion occurred.
Appropriate specimen handling is critical to ensure specimen integrity and the accuracy of
quantitative and qualitative nucleic acid detection. Inappropriate specimen handling can re‐
sult in nucleic acid degradation, which can lead to erroneous quantitation of target from the
patient. For example, RNA is rapidly degraded by a variety of ribonuclease (RNase) en‐
zymes that are abundantly present within cells, on the skin surfaces, and possibly laboratory
bench tops and equipment. RNases are very stable, active in virtually any aqueous environ‐
ment, and can regain their activity after denaturation, and steps need to be developed to
prevent RNA degradation by exposure to contaminating RNases.
2.6. Contamination prevention measures in a PCR laboratory
Millions of copies of target DNA are generated when PCR and other in vitro nucleic acid
amplification techniques are used. If precautions are not taken, amplicons from previous re‐
actions can be introduced into new amplification reactions and act as substrates for new
DNA synthesis. The contaminating amplicons, amplified along with the patient samples
will produce false positive results. Clinical molecular laboratories must have strict policies
regarding contamination prevention and unidirectional work flow. Amplicon contamination
and false positive results are prevented by using physical barriers and chemical and ultra‐
violet (UV) techniques to destroy amplicons or make them unsuitable for amplification. The
physical barriers involve doing separate procedure steps in specially designated areas. For
example, DNA isolation and PCR set-up are done in areas, separated by a wall, from areas
used in downstream processing (thermal cycling, data analysis). This is also known as uni‐
directional work flow. Each area must have designated equipment and supplies to avoid
cross contamination. Laminar flow hoods and other biological containment boxes equipped
with UV light must be available in pre-PCR areas. Small scale physical separation techni‐
ques also include the use of barrier pipette tips, frequent glove changes, designated lab
coats, and PCR tube openers or careful, slow opening of tubes to prevent aerosolization of
contents. Chemical techniques include daily cleansing with bleach and other specialized de‐
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contaminants of work areas before and after use. Use of UV light will further degrade any
residual nucleic acids on work surfaces. A no template PCR reaction must be included with
every assay as a quality control check for amplicon contamination.
3. Assay validation
For a test to become generally useful, it must have demonstrated analytic validity and clini‐
cal utility. Analytic validation focuses on determining how accurately and reliably the assay
measures the molecular event of interest. The assay must be reliable in routine laboratory
setting using a variety of specimen types. Even assays that are routinely performed in the
laboratory require analytic validation within the clinical setting of each laboratory when test
results are used for clinical decisions. To ensure reproducible findings, clinical laboratories
need to understand the impact that preanalytic variables and specimen processing have on
assay performance. Analytic validation ensures that the same answer will be produced for
the same sample within predefined technical variation. In recognition of the critical impor‐
tance of analytic validation for biomarkers, multiple groups have developed recommenda‐
tions and frameworks with which to standardize the assessment.
Clinical validation assesses the strength of association between the assay results and the
clinical outcome of interest, whether it is diagnostic, prognostic, or predictive. A large num‐
ber of measures are used to assess these associations. These analyses address whether one
can be sure the clinical state is positive if the test is positive (positive predictive power) and
that the clinical state is negative if the test is negative (negative predictive power).
Evaluation of new biomarkers can be aided if tumor biomarker studies and the journals re‐
porting them adhere to the Reporting Recommendations for Tumor Marker Prognostic
Studies (REMARK). These guidelines were produced by a working group convened as part
of the NCI-EORTC joint meeting on Cancer Diagnostics in Nyborg, Denmark, in 2000 [51].
REMARK criteria include specifications of patient populations, biological specimen under
study, assay methods, study design, and statistical methods, and detailed guidelines for
analysis and presentation of data. This reporting standard is now requested for manuscripts
being submitted to many journals. Although the tissue sources are not always available to
allow the most rigorous validation of assays, providing a standardized means to communi‐
cate the level of clinical validation is critical to biomarker development. Using the above re‐
porting standards should help establish the clinical validity of new biomarkers being used
in cancer research and treatment.
An emerging standard for the adoption of new molecular tests is the demonstration of clini‐
cal utility. Clinical utility refers to the ability of the assay to improve clinical decision mak‐
ing and patient outcomes. Clinical utility depends on the clinical situation, availability of
effective therapies, magnitude of clinical benefit, and relative value the patient, caregiver,
and society place on the differences in benefits and risks in these separate groups. For exam‐
ple, if a marker clearly distinguishes differences between positive and negative results but
the evidence for differential treatment is not available, there is no reason to test for the
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marker. Likewise, if therapy is effective regardless whether the patient tests positive or neg‐
ative, the marker does not have clinical utility. Additionally, a novel assay might have out‐
standing analytic validity and proven clinical validity but there is already an established
method to test for the same parameters, which makes the new assay unnecessary.
Associations such as Clinical Laboratory Standards Institute (CLSI) have published several
guidelines dealing with molecular genomic testing in clinical laboratories. As more molecu‐
lar tests are being introduced for patient management, CLSI will likely continue to publish
new and expanded guidelines addressing current and possibly future considerations and
best practices.
3.1. Issues with MGMT assay validation
Molecular markers in general are developed to address a variety of indications [52]. Diag‐
nostic markers are a large category of molecular tests that aid in the diagnosis or subclassifi‐
cation of a particular disease state. Diagnostic subclassification may result in different
management of the disease, but the marker is used primarily to establish the particular dis‐
ease that is present in the patient sample. An example of a diagnostic marker is BCR/ABL
t(9;22) translocation in chronic myelogenous leukemia. Prognostic markers have an associa‐
tion with some clinical outcomes, such as overall survival or recurrence-free survival, inde‐
pendent of the treatment rendered. An example of a prognostic marker is the FLT3 IDT
mutation in acute myeloid leukemia, which identifies a subset of patients who will have a
more aggressive disease course regardless of current treatment options. Predictive markers
predict the activity of a specific class or type of therapy, and are used to help make more
specific treatment decisions. They are used as indicators of the likely benefit of a specific
treatment to a specific patient. Human epidermal growth factor receptor (EGFR) is an exam‐
ple of a predictive marker. Patients with lung cancers whose tumors exhibit adenocarcinoma
histology and carry one of the sensitizing EGFR mutations are likely to respond well to
treatment with tyrosine kinase inhibitors erlotinib and gefitinib. Some of these markers may
also be used as companion markers to identify a subgroup of patients that are likely to re‐
spond to a specific therapy. One example of a companion diagnostic is the BRAF V600E mu‐
tation test which is coapproved with the kinase inhibitor vemurafenib. BRAF mutations are
found in 30% to 60% of melanomas, and the kinase activating BRAF V600E mutation confers
sensitivity to vemurafenib, a small molecule inhibitor.
The clinical utility of the MGMT methylation status as a biomarker for benefit from alkylat‐
ing agent therapy in gliomas is still being evaluated and there is no consensus as to which
procedure is most suitable for routine clinical testing. While most protocols measure the lev‐
el of methylation accurately, presence of contaminating normal cells in every specimen
makes it difficult to set up a consistent cut off point between low positive and negative test
results. The extent of methylation required and the sets of CpGs that are crucial for complete
silencing are still under investigation. Given the complexity of the biological relationship be‐
tween promoter methylation and gene silencing and the difficulties to integrate these fea‐
tures into a test that is in addition complicated by presence of nontumoral tissue, there are
unavoidable drawbacks for any technology attempting to predict loss of MGMT expression
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for potential benefit from alkylating agent therapy. Key to introducing tests for diagnostics
is their careful prospective validation.
3.2. MGMT methylight assay validation - A one lab experience
Epigenetic silencing of the MGMT gene through promoter hypermethylation and resulting
transcriptional inactivation is now routinely used as a prognostic and possibly predictive bi‐
omarker in evaluating treatment choices in patients diagnosed with glioma. Patients enroll‐
ing in clinical trials are also evaluated for the MGMT promoter methylation status. For that
reason, a sensitive, clinically validated assay for detection of MGMT promoter methylation
can be of great help in patient management.We previously developed a simplified MGMT
MSP protocol [53] that utilized formalin fixed paraffin embedded specimens. This MSP pro‐
tocol proved reliable with majority of glioma patients, however, result interpretation was
sometimes challenging when evaluating specimens with few malignant cells and/or exten‐
sive necrosis, both of which gave faint bands on agarose gels.To further enhance our ability
to accurately assess methylation status of the MGMT promoter region in glioma specimens,
we investigated the use of real-time PCR technology as a way of enhancing assay sensitivity.
Our ultimate goal was to develop a more sensitive detection method that would give relia‐
ble, semi-quantitative results, even with suboptimal specimens. Previous studies have
shown sodium bisulfite conversion to be a reproducible method, with subsequent quantita‐
tive real-time PCR methylation assays having acceptable precision for clinical work [54].
The goal of this study was to evaluate the MethyLight protocol, as compared to the MGMT-
MSP protocol, and appropriateness of the MethyLight protocol for use in MGMT promoter
methylation detection in routine clinical testing of glioma cases.
3.3. Materials and methods
3.3.1. Tumor samples
Thirty archival brain resection cases were selected for the study: glioblastomamultiforme
(18), oligodendroglioma (3), anaplastic oligodendroglioma (3), and astrocytoma (6). For all
tumor samples, histology was reviewed to confirm diagnosis and select blocks with greatest
tumor involvement. Microdissection was performed on all samples showing an estimated
tumor cell content of less than 50% except in cases where infiltrative pattern of tumor
growth made this step unreliable.
3.3.2. DNA extraction and bisulfite treatment
Genomic DNA was isolated from 2 to 3 twenty micrometer thick paraffin sections after con‐
firmation of the histology. DNA from formalin fixed, paraffin embedded tissue was extract‐
ed using Puregene kit (Gentra Systems, Minneapolis, MN). MGMT promoter methylation
status was assessed using a two step approach. The first step involved bisulfite conversion
of isolated DNA (200-500 ng) which was done using EZ DNA Methylation Gold kit (Zymo
Research, Orange, CA). The second step involved detection of methylated and unmethylat‐
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ed DNA sequences, and was done using the following methods: 1) Methylation specific PCR
(MSP) and 2) Real-time PCR amplification (MethyLight).
3.3.3. Methylation-specific PCR
MGMT MSP amplification was performed as previously reported [53] with specific primers
designed to distinguish methylated from unmethylated DNA. Methylated and unmethylat‐
ed DNA sequences were detected on 2.5% agarose gels. Samples giving signals approxi‐
mately equivalent to the positive methylated control were designated as methylated.
Samples giving no signals with positive methylated control, but demonstrating presence of
unmethylated DNA, similar to the negative control, were designated as unmethylated.
3.3.4. Quantitative real-time PCR (MethyLight)
Real-time PCR assays were set-up in parallel to measure MGMT methylation. Two sets of
primers and probes designed specifically for bisulfite-converted DNAwere used [55]: a set
for MGMT gene and a set for collagen 2A1 (COL2A1) to normalize for the amount of input
DNA. The MGMT forward primer is 5’-GCG TTT CGA CGT TCG TAG GT-3’, the MGMT
reverse primer is 5’-CAC TCT TCC GAA AAC GAA ACG-3’, and the MGMT probe is
6FAM-5’-CGC AAA CGA TAC GCA CCG CGA-3’BHQ1. COL2A1 forward primer is 5’-TCT
AAC AAT TAT AAA CTC CAA CCA CCA A-3’, the COL2A1 reverse primer is 5’-GGG
AAG ATG GGA TAG AAG GGA ATA T-3’, and the COL2A1 probe is 6FAM-5’-CCT TCA
TTC TAA CCC AAT ACC TAT CCC ACC TCT AAA-3’BHQ1. We used Rotor Gene 3000 re‐
al-time PCR instrument (Qiagen, Germantown, MD, USA). The PCR conditions were as pre‐
viously described [56, 57]. Briefly, PCR amplification was performed in 0.2 ml PCR tubes
with a final reaction mixture of 25 µl consisting of 12.5 µl of TaqMan Universal Master mix
without uracil DNA glycosylase (Applied Biosystems, Foster City, CA), 3 µl of respective
forward and reverse primers (10 µM) for either MGMT or COL2A1, 1 µl of probe, 5 µl
(about 50 ng) of bisulfite-modified DNA, and water. PCR conditions were as follows: 95ºC
for 10 min, followed by 50 cycles at 95ºC for 15 s and 60ºC for 1 min.
3.3.5. Assay controls
For assay controls, methylated DNA and unmethylated DNA were purchased from Chemi‐
con International, Temecula, CA, and used as positive and negative controls for methylated
sequences. The control DNA was subjected to bisulfite treatment and PCR amplification in
parallel with patient samples for every run. Controls without DNA were also performed for
each set of reactions. Additionally, for the MethyLight protocol, collagen 2A1 (COL2A1)
gene was used as the internal reference to assess the quality and quantity of input DNA.
3.3.6. Results
To determine the limit of detection of the MehtyLight protocol, bisulfite treated methylated
control DNA was serially diluted into bisulfite treated unmethylated control DNA. DNA
mixing study with methylated and unmethylated DNA showed good linearity. The limit of
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detection of the MethyLight assay was determined to be 1% of methylated DNA in the back‐
ground of unmethylated DNA. The MSP protocol was shown to be slightly less sensitive,
with the limit of detection of 5% of methylated DNA in unmethylated background [53].
Tube No. % of Methylated DNA % of Unmethylated DNA Cycle Threshold(Ct)
1 100 0 28.80
2 50 50 29.77
3 20 80 30.77
4 10 90 31.83
5 5 95 32.74
6 1 99 35.22
7 0 100 0
8 0 0 0
Table 3. Cycle threshold values of serial dilution of methylated DNA into unmethylated control DNA
To evaluate run-to-run variations, we tested the reproducibility of the MethyLight assay by
performing eight independent runs of the serially diluted methylated control in the negative
control background. Acceptable reproducibility was demonstrated between runs.
Of the 30 tumor specimens in the study group, we were able to extract DNA of sufficient
quantity and quality to allow us to determine MGMT promoter methylation status for all
samples. There was a complete concordance in test results between the two methods for
25/30 cases (83%). Overall, methylation specific PCR (MSP) identified 16 (53%) specimens as
positive (methylated MGMT promoter was present) and 14 (47%) of tumors as negative
(having unmethylatedMGMT promoter). The MethyLight protocol identified 15 specimens
(50%) as positive for MGMT promoter methylation. Among the discordant cases, two sam‐
ples tested negative by MSP and were low positive by MethyLight; low DNA recovery was
observed for both of these samples, and the small amount of bisulfite treated DNA that was
available for analysis might have contributed to the discordance in results. The other three
discordant cases tested as weak positive with MSP and were negative by MethyLight; all
three of these cases had significant amount of necrotic tissue, which complicated interpreta‐
tion of the MSP results.
As regards assay controls, in the MSP protocol, MGMT promoter hypermethylation was al‐
ways accompanied by amplification in the unmethylated reaction as well. This is to be ex‐
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pected since the original tissue sections contained a mixture of tumor and non-malignant
tissue. The presence of unmethylated promoter served as an internal amplification control
that confirmed that the quality and quantity of bisulfite treated DNA was acceptable for
clinical testing. Only tumor samples that contained a clearly visible methylated signal, with
or without an additional unmethylated signal, were interpreted as positive for the MGMT
promoter methylation. All the samples that only amplified with unmethylated primers were
interpreted as negative. COL2A1 internal control was used with the MethyLight protocol to
assess the quality and quantity of DNA. All samples demonstrated positive signals with the
COL2A1 PCR amplification.
In comparing the two quality control methods, we observed 100% concordance between the
two systems, with both methods indicating that all samples in the study group contained
sufficient amount of bisulfite converted DNA for clinical testing. The gel signals observed
with unmethylated DNA as an indicator of DNA quantity with the MSP protocol, and the
expression of COL2A1 as an internal control standard in the MethyLight protocol proved to
be equivalent and reliable indicators of quality of input DNA.
This study reports an improvement on our previously published MSP protocol for the detec‐
tion of MGMT promoter methylation in glioma specimens. MethyLight protocol, a real-time
PCR based approach, was used in a number of application [54, 55-57]. In our laboratory, the
MethyLight assay proved to be easy to perform, reproducible, and sensitive in detecting the
amount of methylated DNA sequences in formalin fixed, paraffin embedded brain tumor
specimens. Furthermore, with the use of the real-time PCR approach, we were able to elimi‐
nate post PCR processing that is integral to the MSP protocol.
Recently Ogino and colleagues [54] performed an in-depth investigation of critical parame‐
ters that influence the success of quantitative DNA methylation analysis after sodium bisul‐
fite conversion of DNA samples from archived formalin-fixed paraffin-embedded tumor
specimens, demonstrating the value of percentage of methylated reference (PMR) estima‐
tion. Our system, however, proved impractical for measurement of PMR.To obtain PMR
measurement in their study, the investigators microdissected tumor tissue to obtain pure
populations of tumor cells. Exclusion of normal tissue allowed for precise calculation of
PMR values, and consequently quantitation of the amount of methylation in each tumor
sample. This approach proved to be impractical for some of the samples in our study due to
the pattern of growth of gliomas, particularly GBM tumors, which grow in an infiltrating
pattern, with many benign cells surrounding a few infiltrating tumor cells. Consequently,
sections of these tumors contain both malignant and normal cells, with no easy way of dis‐
secting out a pure tumor population, unless one performs laser capture microdissection.
Since our aim was to optimize a simple MGMT promoter methylation detection assay for
routine clinical use, we continued our practice of histology review and preselecting tissue
blocks with greatest amount of tumor involvement and smallest amount of necrosis prior to
analysis. Using the entire tissue block section proved to be a practical approach for routine
testing in our laboratory, even when microdissection was not possible. At 1% sensitivity, we
were able to detect MGMT promoter methylation even when tumor cells were in minority,
as assessed by review of histology.
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While this study group consisted of a relatively small number of samples, we were able to
develop a testing protocol using MethyLighttechnique, that proved to be reliable and repro‐
ducible in a clinical setting. When applying this method to clinical use, it is important that
proper controls be included with every assay run.After bisulfite treatment of isolated DNA,
patient samples are tested in duplicates for the evidence of MGMT promoter, and for the ex‐
pression of COL2A1 internal control sequences to normalize for input DNA. Additionally,
three different concentrations (100%, 10% and 1%) of methylated DNA in unmethylated
background are run as reference standards. This approach allows clear distinction between
positive and negative signals. The assay results are interpreted as positive or negative for
MGMT promoter methylation. In terms of patient management, temozolomide is give to all
patients, regardless of MGMT promoter methylation status. It has been established that
strongly positive patients will respond to temozolomide, however it is less clear how low
positive patients will respond. When very low positive results are reported for a glioma
specimen, the amount of tumor involvement in that particular sample, as assessed by re‐
view of histology, can serve as an additional guide for the clinical care provider.
In summary, while both MSP and MethyLight detection methods proved acceptable for clin‐
ical testing, with 83% concordance between the two methods, the MethyLight method
proved superior in several different areas. It allowed easier interpretation of low positive re‐
sults, because there was a clear distinction between positive and negative signals. This real-
time, quantitative approach also allowed for reduced turn around time and high throughput
specimen processing, because post PCR gel analysis steps were eliminated. Finally, the
MethyLight method appeared to be more sensitive, even though the significance of very low
positive results is unknown. The limit of detection of the MethyLight assay was determined
to be 1% of methylated DNA in the background of unmethylated DNA, compared to 5%
with the MSP assay.
3.4. Regulation of molecular genomic testing
Molecular testing falls under high complexity testing and is highly regulated. In the United
States two federal agencies, the Food and Drug Administration (FDA) and the Centers for
Medicare and Medicaid Services (CMS) have jurisdiction over this type of testing. The laws
and policies concerning the development and implementation of molecular tests continue to
evolve. Medical tests are regulated by the Center for devices and Radiologic Health, a
branch of FDA. Devices are divided into 3 classes based primarily on the risks associated
with their intended use. Class I tests are low risk, usually of a simple design. Class II tests
pose moderate risks, are evaluated by the FDA through review of a 510(k) premarket notifi‐
cation, and are cleared for marketing once they are found to be substantially equivalent to a
legally marketed device that was previously cleared by the FDA. Class III tests are those as‐
sociated with the highest clinical risk. Each Class III test is reviewed through application for
premarket approval (PMA). A demonstration of safety and effectiveness is needed to gain
FDA approval. The FDA approval/clearance process provides reasonable assurance of safety
and effectiveness, and that the test will provide clinically significant results.
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Figure 6. Oligodendroglioma, WHO grade II. (A) Sections show moderately cellular glial neoplastic proliferation. Tu‐
mor tissue tested positive for MGMT promoter methylation and 1p19q codeletion. (B) The IDH1 R132H is positive.
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The rapid transition of new scientific knowledge to medical practice has led to development
and use of diagnostic tests that are often called laboratory developed tests (LTDs). The FDA
retains jurisdiction over this category of tests and until recently the oversight was basically
directed towards critical reagents used to build these tests. With LTDs being used more
widely in clinical decision making it is likely the FDA will develop clinical guidelines on
Companion Diagnostics or molecular tests which directly impact the use of a pharmaceuti‐
cal or biologic drug.
Clinical laboratories are governed through the Clinical Laboratory Improvement Amendment
(CLIA) of 1988 administered by CMS. CLIA certification is a descriptor which is frequently as‐
sociated with analytically valid assays performed in a clinical laboratory or a laboratory that
has received a CLIA certification. CLIA certification requires that a laboratory adopt specific
practices and perform prescribed measures of analytic validation while performing specific as‐
says. Assays must be performed in CLIA certified laboratories if the results of the assays are
going to be used to guide patient management. Key components of the regulation and over‐
sight of CLIA accredited laboratories are inspections and proficiency tests. In most hospitals
these are provided by the College of American Pathologists (CAP). CAP inspection guidelines
essentially set the standards for overall biomarker laboratory operation, including assay vali‐
dation, quality control, and quality assurance activities. The guidelines mandate regular profi‐
ciency  testing  for  every  clinical  assay,  and  CAP  runs  an  extensive  program  providing
proficiency testing samples for all commonly used clinical assays.
4. Prognostic and predictive relevance of glioma biomarkers
Cancer-specific DNA methylation changes are hallmarks of human cancers, in which global
hypomethylation is often seen concomitantly with hypermethylation of CpG islands. Pro‐
moter CpG island hypermethylation generally results in transcriptional silencing of the as‐
sociated gene [58]. There have been several reports of promoter-associated CpG island
hypermethylator phenotype in human GBM and other glioma subtypes [59-61]. Several
studies have reported differences between primary and secondary GBMs with respect to ep‐
igenetic changes. Overall, secondary GBMs have a higher frequency of promoter methyla‐
tion than primary GBMs [62]. Analysis of epigenetic changes from The Cancer Genome
Atlas study [63] identified the existence of a proportion of GBM tumors with highly con‐
cordant DNA methylation of a subset of loci, indicative of a CpG island methylator pheno‐
type (G-CIMP). G-CIMP positive samples were associated with secondary or recurrent
(treated) tumors and tightly associated with IDH1 mutation. G-CIPM tumors also showed a
relative lack of copy number variation commonly observed in GBM. Integration of the DNA
methylation data with gene expression data showed that G-CIMP tumors represent a subset
of proneural tumors. G-CIMP -positive tumors showed a favorable prognosis with GBMs as
a whole and also with the proneural subset. These data suggest that G-CIMP-positive status
may confer favorable outcome. When lower grade tumors were examined, nearly 10-fold
more G-CIMP-positive gliomas were detected among grade II tumors as compared to grade
IV GBMs. The study suggests that the improved survival of G-CIMP gliomas at all tumor
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grades might be due to certain molecular features within the G-CIMP gliomas that encour‐
age a less aggressive tumor phenotype.
Low grade diffuse gliomas WHO grade II (diffuse astrocytoma, oligoastrocytoma, oligoden‐
droglioma) are characterized by frequent IDH1/2 mutations (>80%) that occur at a very early
stage. In addition, the majority of diffuse astrocytomas (about 60%) carry TP53 mutations,
which constitute a prognostic marker for shorter survival. Limited data exists correlating
IDH1/2 mutations with loss of heterozygosity (LOH) on chromosome arms 1p and 19q,
methylation of the promoter region of DNA repair enzyme O-6-Methylguanine DNA meth‐
yl transferase (M-MGMT) rendering sensitivity to DNA alkylating agents, and epidermal
growth factor receptor variant III (EGFRvIII), a constitutively active mutant form of EGFR
frequently present in glioblastoma.
Diagnosis GR Micro
dissected
IDH1
(+/total)
IDH2 (+/
total)
MGMT
(+/total)
EGFRvIII
(+/total)
LOH
(+/total)
GBM IV 5/20 0/20 0/20 10/20 3/20 nd
0 II 5/14 12/14 1/14 10/13 0/3 10/13
AO III 0/2 2/2 0/2 1/2 0/1 1/1
A II 2/6 2/6 0/6 3/6 0/4 0/2
AA III 0/6 0/6 0/6 3/6 0/4 0/2
OA II/III 3/8 8/8 0/8 6/7 0/4 2/8
AOA III 1/6 1/6 0/6 3/5 0/3 3/3
Table 4. Biomarker distribution among different glioma types
High throughput profiling techniques in conjunction with sophisticated bioinformatics inte‐
grative tools are emerging to revolutionize our knowledge about the complexity of the dis‐
ease. Development of novel array-based profiling techniques and next generation
sequencing techniques has facilitated development of sophisticated tumor-specific genomic
and transcriptional signatures. Integrative analysis of DNA copy number, gene expression
and DNA methylation profiling indicate that molecular alterations may impact future treat‐
ment strategies. For example, as PIK3R1 encodes the regulatory protein p85a subunit, re‐
sponse to PI3K inhibitors may depend on whether the tumors bear mutations in this specific
gene or not. Also, in predicting sensitivity and the development of resistance to temozolo‐
mide the Cancer Genome Atlas network added further support for a role of the DNA mis‐
match repair system. MGMT methylation in conjunction with temozolomide treatment may
lead to a loss of mismatch repair function by introduction of mutations in mismatch repair
genes [64, 65]. Thus patients who initially respond to front line therapy may evolve treat‐
ment resistance by developing a hypermutator phenotype. As a consequence, selective strat‐
egies targeting mismatch repair deficient cells might have to be used in combination with
alkylating agent therapy to prevent or minimize resistance to temozolomide.
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5. Conclusion
The list of clinically useful biomarkers in gliomas is expected to expand as novel markers are
validated in large scale clinical trials [52]. MGMT promoter methylation is now routinely
performed in many institutions. Alkylating agents cause cell death by forming cross-links
between adjacent strands of DNA due to alkylation of the O6 position of guanine. The cellu‐
lar DNA repair protein O6-methylguanine-DNA methyltransferase (MGMT) functions as a
DNA repair enzyme that removes the mutagenic alkyl-adducts from the O6-poasition of
guanine and thereby causes resistance to alkylating drugs [66-68]. 1p/19q LOH has shown
clinical utility, and is a part of guidelines for all oligodendroglioma and mixed tumor man‐
agement. Some of the newer markers, such as IDH1/2 mutations and EGFRvIII mutations
still need further evaluation, and are being used with increasing frequency to provide fur‐
ther definition of tumor stage and possibly subsequent behavior. Molecular laboratories are
likely to evolve also, as clinical care providers continue to rely on genomic-type assays for
guiding patient treatment.
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